Success Metrics

Clinical Success Rate
88.9%

Based on 24 completed trials

Completion Rate
89%(24/27)
Active Trials
2(6%)
Results Posted
46%(11 trials)
Terminated
3(10%)

Phase Distribution

Ph early_phase_1
1
3%
Ph phase_3
5
16%
Ph not_applicable
1
3%
Ph phase_1
5
16%
Ph phase_4
15
48%

Phase Distribution

6

Early Stage

0

Mid Stage

20

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
1(3.7%)
Phase 1Safety & dosage
5(18.5%)
Phase 3Large-scale testing
5(18.5%)
Phase 4Post-market surveillance
15(55.6%)
N/ANon-phased studies
1(3.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

24 of 28 finished

Non-Completion Rate

14.3%

4 ended early

Currently Active

2

trials recruiting

Total Trials

31

all time

Status Distribution
Active(2)
Completed(24)
Terminated(4)
Other(1)

Detailed Status

Completed24
Terminated3
Recruiting1
unknown1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
2
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.7%)
Phase 15 (18.5%)
Phase 35 (18.5%)
Phase 415 (55.6%)
N/A1 (3.7%)

Trials by Status

terminated310%
recruiting13%
unknown13%
withdrawn13%
active_not_recruiting13%
completed2477%

Recent Activity

2 active trials
Showing 5 of 31
active_not_recruitingearly_phase_1

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

NCT05921448
recruitingphase_4

Characterizing the Human Airway Immune Response to FluMist Vaccination

NCT07177417
withdrawnphase_4

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

NCT03884296
completedphase_4

Self-Administered Nasal Influenza Feasibility Study

NCT01933048
completedphase_4

Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)

NCT03023683
View all 31 trials

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT05921448Early Phase 1

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

Active Not Recruiting
NCT07177417Phase 4

Characterizing the Human Airway Immune Response to FluMist Vaccination

Recruiting
NCT03884296Phase 4

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

Withdrawn
NCT01933048Phase 4

Self-Administered Nasal Influenza Feasibility Study

Completed
NCT03023683Phase 4

Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)

Completed
NCT03453801Phase 1

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

Completed
NCT03028974Phase 4

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Completed
NCT01591473Phase 1

Safety Study of FluMist With and Without Ampligen

Terminated
NCT03020498Phase 4

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

Completed
NCT00538512Phase 4

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

Completed
NCT03028987Phase 4

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

Terminated
NCT00112112Phase 1

Safety Study to Evaluate FluMist in Immunocompromised Children

Completed
NCT03023709Phase 4

Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)

Terminated
NCT03023553Phase 4

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

Completed
NCT01938170Not Applicable

Home Administration of FluMist by Parents/Caregivers

Completed
NCT01885169

LAIV (Flumist®) Administration in CF Patients

Unknown
NCT00113880

A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

Completed
NCT00569894

A Post Marking Study to Evaluate the Safety of FluMist in Children

Completed
NCT01484522

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

Completed
NCT00906750Phase 1

A Study of a Live Intranasal Influenza Vaccine in Children With Cancer

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
31